PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30610588-2	2019	Thus, we hypothesized that the addition of metformin to everolimus and exemestane, could lead to better outcomes in overweight and obese patients with metastatic, hormone receptor-positive, HER2-negative breast cancer.	Metformin	43-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	190-194	
30610588-3	2019	We conducted a phase II trial to evaluate the efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal women with metastatic, hormone receptor-positive, HER2-negative breast cancer.	Metformin	88-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	214-218	
30610588-11	2019	Conclusion The combination of metformin, everolimus and exemestane was safe and had moderate clinical benefit in overweight and obese with patients metastatic, hormone receptor-positive, HER2-negative breast cancer.	Metformin	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	187-191